The effect of magnesium on bioactivity, rheology and biology behaviors of injectable bioactive glass-gelatin-3-glycidyloxypropyl trimethoxysilane nanocomposite-paste for small bone defects repair

Injectable bioactive glass-based pastes represent promising biomaterials to fill small bone defects thus improving and speed up the self-healing process. Accordingly, injectable nanocomposite pastes based on bioactive glass-gelatin-3-glycidyloxypropyl trimethoxysilane (GPTMS) were here synthesized via two different glasses 64SiO2. 27CaO. 4MgO. 5P2O5 (mol.%) and 64SiO2.31CaO. 5P2O5 (mol.%). In particular, the effects of MgO on bioactivity, rheology, injectability, disintegration resistance, compressive strength and cellular behaviors were investigated. The results showed that the disintegration resistance and compressive strength of the composite were improved by the replacement of MgO; thus, leading to an increase in the amount of storage modulus (G′) from 26800 to 43400 Pa, equal to an increase in the viscosity of the paste from 136 × 103 to 219 × 103 Pa s. Since the release rate of ions became more controllable, the formation of calcite was decreased after immersion of the Mg bearing samples in the SBF solution. Specimens’ cytocompatibility was firstly verified towards human osteoblasts by metabolic assay as well as visually confirmed by the fluorescent live/dead staining; finally, the ability of human fibroblasts to penetrate within the pores of 3D composites was verified by a migration assay simulating the devices repopulation upon injection in the injured site

Corrigendum to: Cohort profile: Extended Cohort for E-health, Environment and DNA (EXCEED)

This is a correction to: International Journal of Epidemiology, Volume 48, Issue 3, June 2019, Pages 678–679j, https://doi.org/10.1093/ije/dyz07

Sailing into a dilemma : an economic and legal analysis of an EU trading scheme for maritime emissions

On the basis of a joint economic and legal analysis, we evaluate the effects of a “regional” (European) emission trading scheme aiming at reducing emissions of international shipping. The focus lies on the question which share of emissions from maritime transport activities to and from the EU can and should be included in such a system. Our findings suggest that the attempt to implement an EU maritime ETS runs into a dilemma. It is not possible to design a system that achieves emission reductions in a cost efficient manner and is compatible with international law

Association of kidney disease measures with risk of renal function worsening in patients with type 1 diabetes

Background: Albuminuria has been classically considered a marker of kidney damage progression in diabetic patients and it is routinely assessed to monitor kidney function. However, the role of a mild GFR reduction on the development of stage 653 CKD has been less explored in type 1 diabetes mellitus (T1DM) patients. Aim of the present study was to evaluate the prognostic role of kidney disease measures, namely albuminuria and reduced GFR, on the development of stage 653 CKD in a large cohort of patients affected by T1DM. Methods: A total of 4284 patients affected by T1DM followed-up at 76 diabetes centers participating to the Italian Association of Clinical Diabetologists (Associazione Medici Diabetologi, AMD) initiative constitutes the study population. Urinary albumin excretion (ACR) and estimated GFR (eGFR) were retrieved and analyzed. The incidence of stage 653 CKD (eGFR < 60 mL/min/1.73 m2) or eGFR reduction > 30% from baseline was evaluated. Results: The mean estimated GFR was 98 \ub1 17 mL/min/1.73m2 and the proportion of patients with albuminuria was 15.3% (n = 654) at baseline. About 8% (n = 337) of patients developed one of the two renal endpoints during the 4-year follow-up period. Age, albuminuria (micro or macro) and baseline eGFR < 90 ml/min/m2 were independent risk factors for stage 653 CKD and renal function worsening. When compared to patients with eGFR > 90 ml/min/1.73m2 and normoalbuminuria, those with albuminuria at baseline had a 1.69 greater risk of reaching stage 3 CKD, while patients with mild eGFR reduction (i.e. eGFR between 90 and 60 mL/min/1.73 m2) show a 3.81 greater risk that rose to 8.24 for those patients with albuminuria and mild eGFR reduction at baseline. Conclusions: Albuminuria and eGFR reduction represent independent risk factors for incident stage 653 CKD in T1DM patients. The simultaneous occurrence of reduced eGFR and albuminuria have a synergistic effect on renal function worsening